Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Lijun Zhang et al.|The Lancet|2014Cited by 4.7k
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Javier Cortés et al.|New England Journal of Medicine|2020Cited by 3.1k
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium StudiesXiaohong R. Yang, Dallas R. English, Päivi Heikkilä et al.|JNCI Journal of the National Cancer Institute|2010Cited by 716
<i>PALB2</i>, <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGSMelissa C. Southey, Robert Winqvist, Katri Pylkäs et al.|Journal of Medical Genetics|2016Cited by 217
Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range EnhancersJuliet D. French, Isabel dos‐Santos‐Silva, Maya Ghoussaini et al.|The American Journal of Human Genetics|2013Cited by 214